EP3092250A4 - Polynucléotides pour la production in vivo d'anticorps - Google Patents

Polynucléotides pour la production in vivo d'anticorps Download PDF

Info

Publication number
EP3092250A4
EP3092250A4 EP15735068.7A EP15735068A EP3092250A4 EP 3092250 A4 EP3092250 A4 EP 3092250A4 EP 15735068 A EP15735068 A EP 15735068A EP 3092250 A4 EP3092250 A4 EP 3092250A4
Authority
EP
European Patent Office
Prior art keywords
polynucleotides
antibodies
vivo production
vivo
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15735068.7A
Other languages
German (de)
English (en)
Other versions
EP3092250A1 (fr
Inventor
Joseph Beene BOLEN
Axel Bouchon
Giuseppe Ciaramella
Eric Yi-Chun Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
Moderna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moderna Therapeutics Inc filed Critical Moderna Therapeutics Inc
Publication of EP3092250A1 publication Critical patent/EP3092250A1/fr
Publication of EP3092250A4 publication Critical patent/EP3092250A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP15735068.7A 2014-01-08 2015-01-08 Polynucléotides pour la production in vivo d'anticorps Withdrawn EP3092250A4 (fr)

Applications Claiming Priority (33)

Application Number Priority Date Filing Date Title
US201461924805P 2014-01-08 2014-01-08
US201461924819P 2014-01-08 2014-01-08
US201461924834P 2014-01-08 2014-01-08
US201461924783P 2014-01-08 2014-01-08
US201461924827P 2014-01-08 2014-01-08
US201461924850P 2014-01-08 2014-01-08
US201461924811P 2014-01-08 2014-01-08
US201461924754P 2014-01-08 2014-01-08
US201461924802P 2014-01-08 2014-01-08
US201461924841P 2014-01-08 2014-01-08
US201461924810P 2014-01-08 2014-01-08
US201461924779P 2014-01-08 2014-01-08
US201461924820P 2014-01-08 2014-01-08
US201461924787P 2014-01-08 2014-01-08
US201461924791P 2014-01-08 2014-01-08
US201461924770P 2014-01-08 2014-01-08
US201461924799P 2014-01-08 2014-01-08
US201461924795P 2014-01-08 2014-01-08
US201461924775P 2014-01-08 2014-01-08
US201461924846P 2014-01-08 2014-01-08
US201461924817P 2014-01-08 2014-01-08
US201461924807P 2014-01-08 2014-01-08
US201461924781P 2014-01-08 2014-01-08
US201461924773P 2014-01-08 2014-01-08
US201461924768P 2014-01-08 2014-01-08
US201461924812P 2014-01-08 2014-01-08
US201461924767P 2014-01-08 2014-01-08
US201461924804P 2014-01-08 2014-01-08
US201461924776P 2014-01-08 2014-01-08
US201461924763P 2014-01-08 2014-01-08
US201461924774P 2014-01-08 2014-01-08
US201461993715P 2014-05-15 2014-05-15
PCT/US2015/010547 WO2015105926A1 (fr) 2014-01-08 2015-01-08 Polynucléotides pour la production in vivo d'anticorps

Publications (2)

Publication Number Publication Date
EP3092250A1 EP3092250A1 (fr) 2016-11-16
EP3092250A4 true EP3092250A4 (fr) 2017-05-24

Family

ID=53524318

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15735068.7A Withdrawn EP3092250A4 (fr) 2014-01-08 2015-01-08 Polynucléotides pour la production in vivo d'anticorps

Country Status (2)

Country Link
EP (1) EP3092250A4 (fr)
WO (1) WO2015105926A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA3162352A1 (fr) 2010-10-01 2012-04-05 Modernatx, Inc. Nucleosides, nucleotides et acides nucleiques modifies, et utilisations connexes
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2791160B1 (fr) 2011-12-16 2022-03-02 ModernaTX, Inc. Compositions de mrna modifiés
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2968391A1 (fr) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Molécules polynucléotidiques à longue durée de vie
EP2971010B1 (fr) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
EP2971165A4 (fr) 2013-03-15 2016-11-23 Moderna Therapeutics Inc Elimination de fragments d'adn dans des procédés de production d'arnm
WO2014152031A1 (fr) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Purification d'acide ribonucléique
WO2014152027A1 (fr) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Procédés de fabrication pour la production de transcrits d'arn
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051169A2 (fr) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Molécules de polynucléotides et leurs utilisations
WO2015196128A2 (fr) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Molécules d'acide nucléique alternatives et leurs utilisations
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
WO2016014846A1 (fr) * 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Polynucléotides modifiés destinés à la production d'anticorps intracellulaires
WO2017049286A1 (fr) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucléotides contenant un lieur morpholino
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
US11719704B2 (en) 2015-12-30 2023-08-08 Momenta Pharmaceuticals, Inc. Methods related to biologics
WO2017200787A1 (fr) * 2016-05-18 2017-11-23 Arizona Board Of Regents On Behalf Of Arizona State University Chimères peptide-adn pour le traitement des cancers à surexpression de her
MX2019000205A (es) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
JP7016168B2 (ja) * 2016-07-26 2022-02-21 学校法人日本大学 歯周炎治療薬及び歯周炎治療用組成物
US20190351055A1 (en) * 2016-11-16 2019-11-21 University Of Baltimore, Maryland Methods for Treating Bone-Related Disorders
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2019136241A1 (fr) 2018-01-05 2019-07-11 Modernatx, Inc. Polynucléotides codant pour des anticorps anti-virus du chikungunya
WO2021074695A1 (fr) 2019-10-16 2021-04-22 Avacta Life Sciences Limited FRACTIONS DE MÉDICAMENTS BISPÉCIFIQUES DE L'INHIBITEUR DE PD-L1 ET DE L'INHIBITEUR DE TGFβ
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CA3170741A1 (fr) * 2020-07-31 2022-02-03 Curevac Ag Melanges d'anticorps codes par des acides nucleiques
EP4277929A1 (fr) * 2021-01-14 2023-11-22 Translate Bio, Inc. Méthodes et compositions pour administrer des anticorps codés par arnm
WO2022234003A1 (fr) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Polypeptides se liant à cd33 avec protéine stefin a
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
WO2023073228A1 (fr) 2021-10-29 2023-05-04 CureVac SE Arn circulaire amélioré pour exprimer des protéines thérapeutiques
WO2023144330A1 (fr) 2022-01-28 2023-08-03 CureVac SE Inhibiteurs de facteurs de transcription codés par un acide nucleique
WO2023218243A1 (fr) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Protéines de fusion de liaison lag-3/pd-l1
WO2023227608A1 (fr) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Vaccin à base d'acide nucléique codant pour un polypeptide antigénique fimh d'escherichia coli
US20240156949A1 (en) 2022-10-28 2024-05-16 Glaxosmithkline Biologicals Sa Nucleic Acid Based Vaccine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075514A2 (fr) * 2004-03-10 2005-08-18 Lonza Ltd. Procede de production d'anticorps
US20130196377A1 (en) * 2011-12-26 2013-08-01 Samsung Electronics Co., Ltd. Protein complex and method of preparing same
US20130195867A1 (en) * 2007-01-09 2013-08-01 Curevac Gmbh Rna-coded antibody
WO2013151666A2 (fr) * 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de produits biologiques et de protéines associées à une maladie humaine
WO2013185067A1 (fr) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Polynucléotides résistant à la nucléase et leurs utilisations
WO2014152774A1 (fr) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Procédés et compositions de délivrance d'anticorps codés par arnm

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129033A2 (fr) * 2009-04-29 2010-11-11 Calmune Corporation Anticorps modifiés pour immunothérapie passive

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075514A2 (fr) * 2004-03-10 2005-08-18 Lonza Ltd. Procede de production d'anticorps
US20130195867A1 (en) * 2007-01-09 2013-08-01 Curevac Gmbh Rna-coded antibody
US20130196377A1 (en) * 2011-12-26 2013-08-01 Samsung Electronics Co., Ltd. Protein complex and method of preparing same
WO2013151666A2 (fr) * 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de produits biologiques et de protéines associées à une maladie humaine
WO2013185067A1 (fr) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Polynucléotides résistant à la nucléase et leurs utilisations
WO2014152774A1 (fr) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Procédés et compositions de délivrance d'anticorps codés par arnm

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015105926A1 *

Also Published As

Publication number Publication date
EP3092250A1 (fr) 2016-11-16
WO2015105926A1 (fr) 2015-07-16

Similar Documents

Publication Publication Date Title
EP3092250A4 (fr) Polynucléotides pour la production in vivo d'anticorps
EP3212231A4 (fr) Anticorps anti-tim -3
EP3212229A4 (fr) Anticorps anti-tim -3
EP3240564A4 (fr) Méthodes de production de polypeptides modifiés par des ctp à action prolongée
EP3166931A4 (fr) Procédé perfectionné pour la préparation d'enzalutamide
EP3192864A4 (fr) Procédé de production d'un tissu progéniteur cérébelleux
EP3237195A4 (fr) Procédés de production d'articles fabriqués à la presse
EP3119806A4 (fr) Anticorps il -21
HUP1400114A2 (en) Method for the production of peptides
EP3177650A4 (fr) Anticorps anti-céramide
EP3181709A4 (fr) Appareil de production de feuillards d'acier
EP3151857A4 (fr) Anticorps anti-blys
EP3112463A4 (fr) Nouvel anticorps anti-présepsine
IL248267B (en) A process for preparing converted cycloserines
EP3233120A4 (fr) Anticorps il -21
EP3138903A4 (fr) Cellules pour la production d'anticorps humain
SI3160985T1 (sl) Postopek za pripravo D-arginil-2,6-dimetil-L-tirosil-L-lisil-L- fenilalaninamida
EP3147369A4 (fr) Procédé de production de protéines de type fibroïne
EP3227246B8 (fr) Processus d'oxy-calcination
EP3127943A4 (fr) Procédé de production de nanoparticules
EP3107883A4 (fr) Procédé de fabrication d'hydrochlorofluorooléfines
EP3182981A4 (fr) Procédé de production d'isomaltooligosaccharides
EP3099655A4 (fr) Procédé de production d'hydrochlorofluorooléfines
EP3242937A4 (fr) Procédés de production d'abiénol
IL241974A0 (en) Process for making erlotinib

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170424

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 19/34 20060101ALI20170418BHEP

Ipc: C07K 16/18 20060101AFI20170418BHEP

Ipc: A61K 39/395 20060101ALI20170418BHEP

Ipc: C07K 16/28 20060101ALI20170418BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MODERNATX, INC.

17Q First examination report despatched

Effective date: 20190802

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20191017